Table 1.

DNMT inhibitors in cancer.

Drug	Therapeutic use	Developmental stage
Nucleoside analogue inhibitors
(1) 5-azacytidine	Myelodysplastic syndrome	Approved [United States-Food and Drug Administration (US-FDA)]
	Acute myeloid leukemia	Phase 2
	Solid tumors	Phase 2
(2) Decitabine	Myelodysplastic syndrome	Approved (US-FDA)
	Acute myeloid leukemia	Approved [European Commission (EC)]
(3) Zebularine	Solid tumors like breast, urinary bladder, hepatocellular cancer	Preclinical
(4) SGI-110	Myelodysplastic syndrome	Phase 1
	Acute myeloid leukemia	Phase 1
	Solid tumors like bladder cancer	Preclinical
Nonnucleoside analogue inhibitors
(1) Procainamide	Solid tumors like bladder, breast, prostate, cervix	Preclinical
(2) Procaine
(3) Epigallocatechin-3-gallate
(4) SGI-1027	Leukemia	Preclinical
(5) Hydralazine	Breast cancer	Phase 2
	Ovarian cancer	Phase 3
	Cervical cancer	Phase 3